...
首页> 外文期刊>Drug Metabolism and Disposition: The Biological Fate of Chemicals >Phase II-selective induction of hepatic drug-metabolizing enzymes by oltipraz -5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione-, 1,7-phenanthroline, and 2,2'-dipyridyl in rats is not accompanied by induction of intestinal enzymes.
【24h】

Phase II-selective induction of hepatic drug-metabolizing enzymes by oltipraz -5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione-, 1,7-phenanthroline, and 2,2'-dipyridyl in rats is not accompanied by induction of intestinal enzymes.

机译:oltipraz -5-(2-pyrazinyl)-4-methyl-1,2,dithiol-3-thione-,1,7-phenothroline和2,2'-dipyridyl的II期选择性诱导肝药物代谢酶在大鼠中不伴有肠内酶的诱导。

获取原文
获取原文并翻译 | 示例
           

摘要

The induction of hepatic and intestinal cytochrome P450, NAD(P)H:quinone oxidoreductase (QOR), glutathione S-transferase (GST), and UDP-glucuronosyltransferase (UGT) activities by intragastric administration of 1,7-phenanthroline, 2,2'-dipyridyl, and oltipraz has been investigated in rats. In the liver, all three compounds induced phase II drug-metabolizing enzymes without inducing overall cytochrome P450 concentrations and, in a direct comparison, all agents induced the enzymes to a greater extent than did the same dose of tert-butyl-4-hydroxyanisole. With a 75 mg/kg daily, 3-day regimen, UGT, GST, and QOR activities were induced by all compounds. The changes in hepatic GST, QOR, and UGT activities induced by N-heterocyclic compounds were accompanied by increases in the amounts of mRNA for GST Ya (2-2.4-fold), QOR (1.6-2.8-fold), and the UGTs UGT2B1 (4-6-fold) and UGT1A6 (4-10-fold). Changes in the amounts of UGT2B1 mRNA and UGT1A6 mRNA were highly correlated (r = 0. 9), but there was no correlation between changes in either UGT2B1 or UGT1A6 mRNA and GST Ya mRNA. No significant mRNA changes were elicited by tert-butyl-4-hydroxyanisole. Neither GST nor UGT activities were induced in the small intestinal mucosa by any agent. QOR activity was slightly induced by oltipraz. The data suggest that requirements for induction of phase II enzymes in the intestine are markedly different from requirements in the liver.
机译:通过在胃内施用1,7-菲咯啉2,2已经在大鼠中研究了'-双吡啶基和奥替普拉。在肝脏中,所有三种化合物均诱导了II期药物代谢酶,而未诱导细胞色素P450的总体浓度,直接比较,与相同剂量的4-羟基叔丁基茴香醚相比,所有试剂均能更大程度地诱导酶。每天75 mg / kg,为期3天的治疗方案,所有化合物均可诱导UGT,GST和QOR活性。 N杂环化合物诱导的肝GST,QOR和UGT活性的变化伴随着GST Ya(2-2.4倍),QOR(1.6-2.8倍)和UGTs UGT2B1的mRNA含量增加(4-6倍)和UGT1A6(4-10-倍)。 UGT2B1 mRNA和UGT1A6 mRNA的量变化高度相关(r = 0. 9),但UGT2B1或UGT1A6 mRNA和GST Ya mRNA的变化之间没有相关性。叔丁基-4-羟基茴香醚没有引起明显的mRNA变化。在任何情况下,小肠粘膜均未诱导GST和UGT活性。 oltipraz轻微诱导了QOR活性。数据表明,肠中诱导II期酶的要求与肝脏中的要求明显不同。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号